Effect of Fenofibrate on Sleep Apnea Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00816829
Recruitment Status : Terminated (The study was prematurely terminated because of slow recruitment)
First Posted : January 5, 2009
Results First Posted : July 7, 2009
Last Update Posted : July 22, 2009
Information provided by:
Solvay Pharmaceuticals

Brief Summary:
Objectives: to investigate for the potential effect of fenofibrate on symptoms and biological changes associated with sleep apnea syndrome.

Condition or disease Intervention/treatment Phase
Dyslipidemia Sleep Apnea Syndrome Overweight Obesity Drug: Placebo Drug: Fenofibrate Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome
Study Start Date : September 2005
Primary Completion Date : January 2008
Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea
Drug Information available for: Fenofibrate
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: 1
Fenofibrate-matching placebo tablet
Drug: Placebo
Fenofibrate-matching placebo tablet
Experimental: 2
145 mg NanoCrystal fenofibrate tablet
Drug: Fenofibrate
145 mg NanoCrystal tablet

Primary Outcome Measures :
  1. Obstructive Apneas [ Time Frame: at one month of treatment ]
  2. Desaturations [ Time Frame: at one month of treatment ]
  3. Sleep Time With Oxygen Saturation Below 90% [ Time Frame: at one month of treatment ]
  4. Apneas [ Time Frame: at one month of treatment ]
  5. Hypopneas [ Time Frame: at one month of treatment ]
  6. Index Apnea/Hypopnea [ Time Frame: at one month of treatment ]
  7. Mixed Apneas [ Time Frame: at one month of treatment ]
  8. Central Apneas [ Time Frame: at one month of treatment ]
  9. Index of Apneas [ Time Frame: at one month of treatment ]
  10. Index of Hypopneas [ Time Frame: at one month of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Having previous diagnosis of sleep apnea not treated with Continuous Positive Airway Pressure (CPAP) or presenting clinical symptoms of sleep apnea
  • Overweight or obese, with BMI >= 25 kg/m² and < 40 kg/m².
  • Known moderate hypertriglyceridemia, with fasting Triglycerides level >= 2.0 and < 6.0 mmol/L within 3 months before the inclusion.

Exclusion Criteria:

  • indication for immediate CPAP
  • other known endocrine disease, except treated and adequately controlled hypothyroidism
  • renal failure or plasma creatinine level >130 µmol/L
  • current chronic liver disease or ALanine Amino Transferase (ALT)> 2 times the upper normal limit (UNL)
  • symptomatic gallbladder disease
  • known muscular disease or creatine phosphokinase (CK) > 3 times UNL.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00816829

Site 1
Paris, France
Sponsors and Collaborators
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jean-Claude Ansquer, Solvay Pharmaceuticals Identifier: NCT00816829     History of Changes
Other Study ID Numbers: C LF178P 05 01
First Posted: January 5, 2009    Key Record Dates
Results First Posted: July 7, 2009
Last Update Posted: July 22, 2009
Last Verified: July 2009

Keywords provided by Solvay Pharmaceuticals:
Sleep Apnea Syndromes
Overweight or obese patients

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Body Weight
Lipid Metabolism Disorders
Metabolic Diseases
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents